A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples